SEC Form 4 · accession 0001012975-18-000025
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Enright
Officer — President and CEO · Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 4:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 | Jan 2, 2018 | M | 183,347 | $0.08 | A | 364,511 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy) | $0.08 | Jan 2, 2018 | M | 183,347 | D | May 4, 2017 | Dec 3, 2021 | Common Stock, par value $0.0001 | 183,347 | 0 | D |